Pacira BioSciences (NASDAQ:PCRX) Reaches New 12-Month Low at $21.83

Pacira BioSciences, Inc. (NASDAQ:PCRXGet Free Report) shares reached a new 52-week low during trading on Tuesday . The stock traded as low as $21.83 and last traded at $21.87, with a volume of 533514 shares traded. The stock had previously closed at $28.46.

Analyst Ratings Changes

Several research analysts recently commented on PCRX shares. HC Wainwright reiterated a “buy” rating and issued a $57.00 price target on shares of Pacira BioSciences in a research report on Tuesday. Piper Sandler reiterated an “overweight” rating and issued a $42.00 price target on shares of Pacira BioSciences in a research report on Wednesday. Needham & Company LLC restated a “buy” rating and set a $43.00 target price on shares of Pacira BioSciences in a research report on Tuesday. JPMorgan Chase & Co. started coverage on Pacira BioSciences in a research report on Thursday, March 7th. They set an “overweight” rating and a $45.00 target price for the company. Finally, Barclays lowered Pacira BioSciences from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $38.00 to $25.00 in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Pacira BioSciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.10.

Read Our Latest Report on PCRX

Pacira BioSciences Stock Down 4.7 %

The company’s 50 day moving average price is $28.60 and its two-hundred day moving average price is $29.73. The company has a quick ratio of 4.78, a current ratio of 5.81 and a debt-to-equity ratio of 0.57. The stock has a market cap of $1.01 billion, a P/E ratio of 15.15 and a beta of 0.88.

Pacira BioSciences (NASDAQ:PCRXGet Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.46 by ($0.04). Pacira BioSciences had a net margin of 10.34% and a return on equity of 12.98%. The company had revenue of $167.12 million for the quarter, compared to the consensus estimate of $165.43 million. As a group, research analysts expect that Pacira BioSciences, Inc. will post 2.13 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Daryl Gaugler sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $28.38, for a total value of $28,380.00. Following the completion of the transaction, the chief operating officer now owns 116,040 shares of the company’s stock, valued at $3,293,215.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Lauren Riker sold 3,970 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $28.72, for a total value of $114,018.40. Following the completion of the transaction, the senior vice president now owns 38,075 shares of the company’s stock, valued at $1,093,514. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Daryl Gaugler sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $28.38, for a total transaction of $28,380.00. Following the completion of the transaction, the chief operating officer now directly owns 116,040 shares of the company’s stock, valued at approximately $3,293,215.20. The disclosure for this sale can be found here. Insiders sold 21,150 shares of company stock valued at $602,170 over the last 90 days. Corporate insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Pacira BioSciences

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Pacira BioSciences by 0.3% during the first quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company’s stock worth $149,413,000 after purchasing an additional 14,960 shares in the last quarter. Frontier Capital Management Co. LLC increased its position in shares of Pacira BioSciences by 15.8% during the fourth quarter. Frontier Capital Management Co. LLC now owns 2,084,542 shares of the company’s stock worth $70,332,000 after purchasing an additional 285,045 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Pacira BioSciences by 1.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,411,767 shares of the company’s stock worth $47,633,000 after purchasing an additional 17,949 shares in the last quarter. Vestal Point Capital LP acquired a new position in shares of Pacira BioSciences during the fourth quarter worth $40,488,000. Finally, Clearbridge Investments LLC increased its position in shares of Pacira BioSciences by 2.3% during the first quarter. Clearbridge Investments LLC now owns 1,172,150 shares of the company’s stock worth $34,250,000 after purchasing an additional 26,463 shares in the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Pacira BioSciences Company Profile

(Get Free Report)

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.

Recommended Stories

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.